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Abstract. Clinical features of 27 cases of Chronic Mountain Sickness (CMS) 
from the Himalayas are reported. They are compared with 75 native high- 
landers (NH). All CMS patients were immigrants to high altitude. Mean 
duration of stay at high altitude was seven years. Mean values for haematocrit 
and haemoglobin were 80% and 23 G% respectively for the CMS group and 
-- , , .z@$&w7.9 G% respectively for the native highlanders group. Mean QRS 
axis in the -tks -tatter +7@.'hfcldenee and quantum 
of protienuria were significantly higher in the CMS group. Cardiac catheteri- - 
sation studies done in eight CMS cases showed elevated Pulmonary Artery (PA) 
pressures even after a mean of 14.2 days at sea level. The disease which has 
four diagnostic elements-hypoxemia and polycythemia, pulmonary hyper- 
tension, right ventricular enlargement and nephropathy with dense proteinuria-is 
a variant of 'Monge's Disease' and a name CMS Phobrang Type is suggested, 
along with a new approach to clinical classification which may help in diagnosis 
before cor pulmonale sets in. Limited therapeutic trials conducted at high 
altitude seem to indicate that yogic deep breathing exercises, low-dose aspirin 
and diamox may be beneficial in the prevention and therapy of CMS Phobrang 
Type at h~gh  altitude. 
1. Introduction 
Chronic Mountain Sickness (CMS) is not uncommon among both the natives and 
immigrants of the Peruvian Ande~ l '~ .  However the disease was considered to be non- 
existent in the Hirnalaya~~'~ till the first series of 13 cases werer reported6 in February 
1982. Subsequently we identified a total of 27 cases of CMS in the Western Himalayas, 
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at altitudes of 11,500 to 16,730 feet above mean sea level6. In this article we present 
our findings in detail. 
CMS has been defined as a variety of hypoxic chronic cor pulmonale4. Prolonged 
exposure to high altitude causes desensitisation of the chemosensitive respiratory 
mechanisms to hypoxia and/or hypercapnoea4'7. This leads to alveolar hypoven- 
tilation, hypoxemia, polycythemia, hyperviscosity states, hypoxic hypertensive pul- 
monary vascular disease and finally to hypoxic chronic cor pulmonale and nephro- 
pathy with gross proteinuria. Sleep hypoxemia due to breathing dysrhythmias may be i /  
a major triggering factor8. According to Heath4, CMS may be the clinical mani- 'i. 
festation of ageing at high altitude being the result of excessive polycythemia secondary > 
to age related fall in ventilatory rate. 
2. Material and Methods 
Twenty seven cases of CMS were studied. All were male immigrants, in robust 
health prior to the onset of the disease, without any history of respiratory diseases 
or of exposure to occupational hazards conducive to  the development of cor pul- 
monale. None had current evidence or past history of cardiac or renal disease. 
Mean age of the cases studied was 36.1 years (range 25 to 48 years). At the time of 
diagnosis, 26 were living at altitudes beyond 13,000 feet and one was at 11,500 feet. 
Mean duration of stay at high altitude (HA) was seven years (range 1.2 to 15.3 years). 
They were compared with 75 native highlanders (NH), for generations inhabitants 
of the Western Himalayas at altitudes of 13,430-14,100 feet abo3- pas*sea level 
(AMSL). Parameters studied were clinical exarnination~wfiich'included a cardiorespi- 
ratory and neurological questionnaire, conventional ECG, skiagram chest, haematologi- 
cal examination (haemoglobin-Hb-, haematocrit-VPRC-, total and differential leucocyte 
cell counts) and urinalysis. Cardiac catheterisation and right heart studies were' 
conducted in eight cases after evacuation to Army Hospital, Delhi Cantt. This in- 
volved unavoidable delays of 4 to 24 days, mean 14.6 days. 
Diagnosis of CMS was made on the basis of clinical features (the classical 
facies, RV heave, accentuated Pa) VPRC above or equal to 70%, ECG evidence of 
RV enlargement (RVE)/RV haemodynamic overload9, prominent main pulmonary 
artery segment (MPA) and proteinuria-cloud or precipitate on the boiling testlo. 
3. Results 
The data are presented in Tables 1 to 7. 
4. Discussion 
Since CMS was not known to exist in the Himalayas, Lahiri thought that factors 
other than HA hypoxia may be playing a vital role in the genesis of the disease3. 
1 
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Table 1. Symptomatology 
Symptoms No. with the symptom % 
Malaise, lethargy, easy fatiguability 19 70.4 
Exertional dyspnoea 16 59.3 
Impairment of memory 16 59.3 
Lack of concentration 16 59.3 
Bleeding Diathesis 9 33.3 
Exertional Angina 7 25.9 
Exertional Palpitation 7 25.9 
Mild GIT symptoms 5 18.5 
Table 2. Clinical signs 
Signs No. with the signs % 
Facies of hypoxemia and polycythemia 27 100 
Palpable and/or accentuated P, 21 77.8 
RV Heave 12 44.4 
Koilonychia/platynychia 18 66.7 
Spleenomega+y-- -- 1 -- .--  - - 3.7 
Phlebothrombosis 1 3.7 
.- Clubbing (Reported as a common finding in the 
Andean CMSJs2.4) 0 0 
Type landers (Banchero) (Reynafarje) 
Altitude (feet AMSL) 14181.5 13765 1 1220 13779.4 
Number 27 75 3 . 12 
Haernatocrit (%) 80.2 47.6 26.83 38 
Haemoglobin (G%) 23.0 17.9 11.8 15.1 
*-A4GkiC "- 28.7 37.6 44.13 39.6 
% with Resting Proteinuria 
No Proteinuria 33.3 82.8 
'Haziness' 0 17.3 
'Cloud' 14.8 0 
'Precipitate' 51.9 0 
ble 4. ECG data 
The Parameters CMS Group NH Group 
QRS Axis + 118.5" + 76" 
Amplitude of P in Lead I1 in mm 1.8 0.9 
RVE/RV Overload seen in 55.6% 28.0% 
LVE by voltage criterion seen In 50.0% 64.0% 
Data on Skiagram Chest 
C:T Ratio 0.44 0.41 
MPA Prominence seen in 91.7% 17.7% 
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Table 5. Haemodynamic data (8 cases) I 
Site Pressures Mean 
Systolic Diastol~c 
- 
Rt Atrium - - 4.5 
(3-5) 
Rt Ventricle 39.5 4.5 
(30-45) (3-5) - 
Pulmonary Artery 37.3 14.4 20.5 
(30-44) (12-18) (1 8-22) 
Pulmonary Wedge - - 11.3 
(5-18) 
-=%. 
Note : 1. Figures in parenthesis indicate the range of pressures. 
2. The time-lag between HA to Catb lab = 14.6 days (4-24 days). 
--- 
Table 6. CMS-Phobrang type versus Monge's disease : a com@t%m . /*.. 
Features CMS Phobrang Type Monge's disease (Penaloza Monge) 
Altitude Majority were above Above 9840 feet 
14000 feet 
Cor pulmonale Seen in only 55.6% Sine que non for diagnosis 
Neuropsychiatric features Not disabling Dominant (Coma, convulsions. 1 
sudden death) 
Cardiorespiratory symptoms Disabling Not common 
Clubbing 
Semnolence 
Insomnia 
Not seen Common , 
C 
Koilonychia/Platynychia Common (66.7%) Not reported 
Table 7. CMS-Phobrang type-the three grades of the disease lrrae~ 
Features Grade I Grade I1 Grade 111 
Disease Disease se 
No of cases 
Mean altitude in feet AMSL 
Mean Haematocrit % 
Mean Haemoglobin G% 
Mean MCHC 
Incidence of 
Proteinuria % 
No proteinuria 
'Haziness' 
'Cloud' 
'Precipitate' 
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This study was undertaken to find out whether CMS exists in the Himalayas or not, 
if i t  does what are its characteristics and how does it compare with Monge's disease 
(eponym for CMS) as seen in the Peruvian Andes. 
!k In the twenty seven cases of CMS identified in this study, the mean age was 
36.1 years (range 25 to 48 years). This is in agreement with the findings of 
Penaloza"'12 and Hurtadols. Mean total HA tenure (THAT) was seven years 
, (range 1.2 to 15.3 years). Mean time lag between last sojourn to plains (LSTP) and 
diagnosis was only 8.9 months (range 1 to 24 months) LSTP was below 1 year in 16 
patients and below 6 months in 6 patients. The duration of LSTP in all of them 
extended between 10 to 18 weeks, periods adequate to achieve resolution of the 
pathophysiological changes of HA4. In the 6 cases with LSTP below 6 months, the 
VPRC values were 74, 71, 72,67,78, and 70%; two of them had proteinuria 'cloud' 
and 4 hzd prot:inuria 'precipitate'. These findings indicate that prolonged exposure 
to HA hypoxia, even in different spells has cumulative effects in hampering cardiac, 
haematological and renal functions loading on to CMS. 
Presenting complaints varied widely, true to the observation of Monge and 
M ~ n g e l ' ~  that the disease is polysymptomatic in its expression effecting any organ 
system (Table 1 and 2). However, we noted that cardiorespiratory symptoms were 
the more distressing ones. We did not come across major neurological problems 
like cerebral crises, coma and convulsions1'2. In spite of the wealth of subjective 
y. These observations lead us to 
form in the H W a y a s  in com- 
parison to the Andean CMS. 
The typical facies of CMS is unmistakeable-plethoric florid face with suffused 
conjunctiva showing injected vessels, cyanosis of lips and buccal mucosa, intensely 
red palms with cyanosed digital tips, koil~nychia/platynychiaB'~, The last two features 
do not seem to have been reported from the Andes. 
CMS group had very high VPRC in comparison to the NH (Table 3). Mean 
corpuscular Hb concentration (MCHC) on the contrary was significantly higher in 
the NH group. This, we believe, is a reflection on the two different approaches 
adopted by the two groups in combating HA hypoxia. This has to be viewed in con- 
cert with our observation that not a single case of CMS was seen in the NH of the 
Himalayas and the observation of Banchero14 and ReynafarjeI6. who found the VPRC 
of the Lamas of Peru somewhat identical to the values noted by us in the NH group. 
We believe that the NH of the Himalayas, over many centuries have adapted to the 
HA hypoxia, whereas their Andean counterparts have only acclimatized to HA 
hypoxia, because that race has been in the Andean mountains for a shorter span of 
time. This would also explain why earlier workers like Lahiria failed to identify 
CMS in the Himalayas, as the search was made only among the NH of the Him- 
alayas. ' Our study was the first systematic attempt made to identify CMS among 
the immigrants to the Himalayas. 
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The lower incidence and quantum of proteinuria, as also the normal QRS axis on 
ECG, and normal skiagram chest of the NH group support the hypothesis me 
ed above (Table 4). 
Cardiac catherisation and right heart studies where done in eight cases. The 
mean time-lag between arrival at sea level and these studies was 14.6 days (range 
4 to 24 c7ays). The mean pulmonary artery pressure was 20.5 mm Hg (Table 5). 
Our CMS group is compared with Monge's disease as described by Monge and 
M ~ n g e l ' ~  and by Penalozall''$ in Table 6. The differences are subtle yet signi- 
ficant, and so we believe that what we see in the Himalayas is,& 
diseases'6. Therefore, we had suggested the name CMS Pho 
entity6 in 1982 (Phobrang is the name of the place from where the first 5 cases 
of our series came). 
In all 27 cases, resolution was spontaneous on evacuation to plains with some 
of them claiming dramatic relief on arrival at sea level2. Relapse on re-induction 
to the mountains was established in case No 27, albeit inad~er tant ly l~ '~~.  
Based on clinical, haematological, radiological, and electrocardiographic data we 
could classify the disease into 3 grades of severity (Table 7). 
Grade I Disease :- They had exaggerated accentuation of HA erythrocytosis 
only (EAHAE); no pulmonary arterial hypertension 
(PAH) or RVE. 
Grade I1 Disease-: 
Grade 111 Disease :- They had EAHAE plus PAH plus RVE. Only Grade 
I11 disease has hypoxic chronic cor pulmoaale, other 
2 grades do not have cor pulmonale. 
-_I. 
Therefore, we believe that CMS Phobrang type can be diagnosed before cor 
pulmonale sets in, and we are reluctant to define the disease as a variety of hypoxic 
chronic cor pulmonale. We would define CMS Phobrang type as a syndrome 
caused by HA hypoxia and characterised by hypoxemia, polycythemia, PAH and 
RVE/RV overload and nephropathy with gross proteinuria, each of which appear 
at different stages in the evolution of the disease and each of which resolve<.b;poa- 
taneously on evacuation to plains only to relapse on re-induction to the mountains. 
When we compared the 3 Grades of the disease, it was found that Grade 111 
disease occurred at higher altitudes (Table 7). VPRC was lower in Grade 111 than 
in Grades I and 11. This raises another possibility; that differing individual re- 
actions to HA hypoxia may be decisive in a given individual contracting Grade I or 
Grade 111 disease. Those who respond primarily through an overP&uction of ery- 
throcytes ("erythropoetin secretors") develop Grade I disease, whereas those who 
respond primarily through pulmonary arteriolar constriction ("vasoreactors") deve- 
lop Grade I11 disease. The same phenomenon causing renal vasoconstriction and 
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renal parenchymal hypoxia17 may explain the significantly higher frequency and 
quantum of proteinuria in Grade 111 disease. 
I Various forms of therapy have been advocated in literature-evacuation to plains, phlebotomy and administration of steroids and of medroxy progesterone 
acetate - a ventilatory s t i m ~ l a n t ~ ' ~ " ~ .  None of them are acceptable in our cir- 
cumstances at HA. Therefore, we evolved a therapeutic regime which w$ call by 
the mnemonic 'DAY'-D for diamox (ventilatory stimulant), A for aspirin (anti 
prostaglandin agent) and Y for yogic deep breathing exercises, which formed the 
central pillar. Cheap, almost non toxic in the doses administered, and available 
in the remotest of mountains, this regime, we feel may help man in developing 
'long-term friendship' with the mountains, as naturally as possible. Limited thera- 
peutic trials were conducted at an altitude of 14,432 feet AMSL in 4 cases over a 
period of 7 days. Results were gratifyinglgJZ0 Mean fall in haematocrit was 3.8%, 
mean fall in amplitude of P waves in lead Ii was 11.8% over pre-treatment values, 
mean left-ward shift of QRS axis was 10.1% over pre-treatment values, LV : RV 
ratio improved by 51% over pre-treatment values. At different altitudes above 
11,500 feet AMSL we tried out this regime of 'DAY' in eight more cases of CMS, 
all with gratifying and some with dramatic r e s ~ l t s ~ " ~ ~ ' ~ ~ .  
5. Conclusion 
.can it CMS 
Phobrang type after the place from where the first five cases came. HA hypoxia is 
the sole incriminating factot in the genesis. Prolonged exposure to HA hypoxia, even 
in different spells has a cumulative effect in hampering cardiac, haematological and 
renal functions leading on to CMS. Role of 'DAY' ,n therapy and prevention of CMS ' 
at HA needs to be further elucidated. 
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